Mucinex Allergy joins lineup

Reckitt Benckiser recently extended its Mucinex brand into the allergy set with the appropriately named Mucinex Allergy. “Super fantastic launch in the United States,” said Heather Allen, Reckitt Benckiser EVP category development, recently to investors. “Allergy is a $2.5 billion market in the United States. More than 75% of Mucinex users also take an allergy treatment, and now, we’re able to offer them Mucinex Allergy, a maximum strength, non-drowsy antihistamine [that] acts fast and lasts for 24 hours.”

(For the complete category review, including data, click here.)